Seeking Alpha

FDA grants Fast-Track designation to GW's Sativex pain treatment

  • GW Pharmaceuticals' (GWPH) Sativex, which is used to treat pain in patients with advanced cancer, has received Fast-Track designation from the FDA.
  • As a cannabinoid medicine, Sativex is the only non-opioid treatment in Phase 3 development for patients who don't respond to, or experience negative side effects, with opioid medications, GW says.
  • Shares are +6.8%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: